AU2017313138B2 - A novel immunoprobe-based method to assess organ injury status through a biofluid-based cell-free DNA (cfDNA) assay - Google Patents

A novel immunoprobe-based method to assess organ injury status through a biofluid-based cell-free DNA (cfDNA) assay Download PDF

Info

Publication number
AU2017313138B2
AU2017313138B2 AU2017313138A AU2017313138A AU2017313138B2 AU 2017313138 B2 AU2017313138 B2 AU 2017313138B2 AU 2017313138 A AU2017313138 A AU 2017313138A AU 2017313138 A AU2017313138 A AU 2017313138A AU 2017313138 B2 AU2017313138 B2 AU 2017313138B2
Authority
AU
Australia
Prior art keywords
urine sample
detection reagent
kidney
cfdna
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017313138A
Other languages
English (en)
Other versions
AU2017313138A1 (en
Inventor
Minnie M. Sarwal
Tara K. SIGDEL
Joshua Y. YANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2017313138A1 publication Critical patent/AU2017313138A1/en
Application granted granted Critical
Publication of AU2017313138B2 publication Critical patent/AU2017313138B2/en
Priority to AU2024202089A priority Critical patent/AU2024202089C8/en
Priority to AU2026201931A priority patent/AU2026201931A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6827—Total protein determination, e.g. albumin in urine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6827—Total protein determination, e.g. albumin in urine
    • G01N33/6839—Total protein determination, e.g. albumin in urine involving dyes, e.g. Coomassie blue, bromcresol green
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Primary Health Care (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2017313138A 2016-08-17 2017-08-17 A novel immunoprobe-based method to assess organ injury status through a biofluid-based cell-free DNA (cfDNA) assay Active AU2017313138B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2024202089A AU2024202089C8 (en) 2016-08-17 2024-04-02 A novel immunoprobe-based method to assess organ injury status through a biofluid-based cell-free dna (cfdna) assay
AU2026201931A AU2026201931A1 (en) 2016-08-17 2026-03-13 A novel immunoprobe-based method to assess organ injury status through a biofluid-based cell-free dna (cfdna) assay

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662376299P 2016-08-17 2016-08-17
US62/376,299 2016-08-17
PCT/US2017/047372 WO2018035340A1 (en) 2016-08-17 2017-08-17 A novel immunoprobe-based method to assess organ injury status through a biofluid-based cell-free dna (cfdna) assay

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024202089A Division AU2024202089C8 (en) 2016-08-17 2024-04-02 A novel immunoprobe-based method to assess organ injury status through a biofluid-based cell-free dna (cfdna) assay

Publications (2)

Publication Number Publication Date
AU2017313138A1 AU2017313138A1 (en) 2019-03-07
AU2017313138B2 true AU2017313138B2 (en) 2024-01-04

Family

ID=61197090

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017313138A Active AU2017313138B2 (en) 2016-08-17 2017-08-17 A novel immunoprobe-based method to assess organ injury status through a biofluid-based cell-free DNA (cfDNA) assay
AU2026201931A Pending AU2026201931A1 (en) 2016-08-17 2026-03-13 A novel immunoprobe-based method to assess organ injury status through a biofluid-based cell-free dna (cfdna) assay

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026201931A Pending AU2026201931A1 (en) 2016-08-17 2026-03-13 A novel immunoprobe-based method to assess organ injury status through a biofluid-based cell-free dna (cfdna) assay

Country Status (7)

Country Link
US (7) US11124824B2 (https=)
EP (2) EP3845665A1 (https=)
JP (1) JP7109424B2 (https=)
CN (2) CN109890977A (https=)
AU (2) AU2017313138B2 (https=)
CA (1) CA3033650A1 (https=)
WO (1) WO2018035340A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
RU2671980C2 (ru) 2011-02-09 2018-11-08 Натера, Инк. Способы неинвазивного пренатального установления плоидности
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
EP4414990A3 (en) 2013-01-17 2024-11-06 Personalis, Inc. Methods and systems for genetic analysis
US20180173846A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
US10125399B2 (en) 2014-10-30 2018-11-13 Personalis, Inc. Methods for using mosaicism in nucleic acids sampled distal to their origin
US11168351B2 (en) 2015-03-05 2021-11-09 Streck, Inc. Stabilization of nucleic acids in urine
US11479812B2 (en) 2015-05-11 2022-10-25 Natera, Inc. Methods and compositions for determining ploidy
US20170145475A1 (en) 2015-11-20 2017-05-25 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
RU2760913C2 (ru) 2016-04-15 2021-12-01 Натера, Инк. Способы выявления рака легкого
US11299783B2 (en) 2016-05-27 2022-04-12 Personalis, Inc. Methods and systems for genetic analysis
WO2018022991A1 (en) 2016-07-29 2018-02-01 Streck, Inc. Suspension composition for hematology analysis control
WO2018035340A1 (en) 2016-08-17 2018-02-22 The Regents Of The University Of California A novel immunoprobe-based method to assess organ injury status through a biofluid-based cell-free dna (cfdna) assay
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
CN115119829B (zh) 2017-10-19 2024-07-12 斯特雷克股份有限公司 用于胞外囊泡的溶血和凝血调节以及稳定化的组合物
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
US12024738B2 (en) 2018-04-14 2024-07-02 Natera, Inc. Methods for cancer detection and monitoring
US11814750B2 (en) 2018-05-31 2023-11-14 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
US10801064B2 (en) 2018-05-31 2020-10-13 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
EP4397771A3 (en) * 2019-01-04 2024-10-16 PreAnalytiX GmbH Urine stabilization
EP3914731A1 (en) * 2019-01-24 2021-12-01 Illumina, Inc. Methods and systems for monitoring organ health and disease
JP7470787B2 (ja) 2019-11-05 2024-04-18 パーソナリス，インコーポレイティド 単一試料からの腫瘍純度の推定
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
EP4263383A4 (en) * 2020-12-17 2024-10-23 Nephrosant, Inc. KITS FOR STABILIZATION OF URINE SAMPLES
EP4373972A4 (en) * 2021-07-23 2025-06-18 Georgetown University USE OF METHYLATED CIRCULATING FREE DNA TO DETECT TISSUE INJURY
WO2023059654A1 (en) 2021-10-05 2023-04-13 Personalis, Inc. Customized assays for personalized cancer monitoring
EP4440429A4 (en) * 2021-11-30 2026-01-28 Nephrosant Inc Generative Antagonist Network for Urinary Biomarkers
US20240124916A1 (en) 2022-09-16 2024-04-18 Illumina Cambridge Limited Nanoparticle with polynucleotide binding site and method of making thereof
WO2025076525A1 (en) * 2023-10-06 2025-04-10 Neutrolis, Inc. Biomarker and precision therapy for inflammatory disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120283128A1 (en) * 2009-12-20 2012-11-08 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2014145232A2 (en) * 2013-03-15 2014-09-18 Organ-I, Inc. Methods and compositions for assessing renal status using urine cell free dna

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0821041B2 (ja) 1988-06-01 1996-03-04 横河電機株式会社 プリント基板ｃａｄの部品シンボル作成方法
US5849517A (en) 1991-05-08 1998-12-15 Streck Laboratories, Inc. Method and composition for preserving antigens and nucleic acids and process for utilizing cytological material produced by same
JPH0821041A (ja) 1994-07-07 1996-01-23 Ig Tech Res Inc 瓦棒葺屋根の改修構造
US5922544A (en) 1994-12-29 1999-07-13 Eiken Kagaku Kabushiki Kaish Method of cell detection
JPH1021041A (ja) * 1996-06-28 1998-01-23 Matsushita Electric Ind Co Ltd 操作パネル
US7537889B2 (en) * 2003-09-30 2009-05-26 Life Genetics Lab, Llc. Assay for quantitation of human DNA using Alu elements
JP2008545418A (ja) * 2005-05-27 2008-12-18 ジョン ウェイン キャンサー インスティチュート 癌の診断、予後診断、および治療のための遊離循環ｄｎａの使用
US20090081678A1 (en) 2007-09-21 2009-03-26 Streck, Inc. Nucleic acid isolation in preserved whole blood
JP2010017178A (ja) 2008-06-11 2010-01-28 Sumitomo Chemical Co Ltd Ｄｎａを定量又は検出する方法
NO2398912T3 (https=) 2009-02-18 2018-02-10
US8404444B2 (en) 2009-02-25 2013-03-26 Diacarta Llc Method for predicting the level of damage to cells by measuring free circulating Alu nucleic acid
US20110027771A1 (en) 2009-07-31 2011-02-03 Artemis Health, Inc. Methods and compositions for cell stabilization
US20110111410A1 (en) * 2009-11-09 2011-05-12 Streck, Inc. Stabilization of rna in intact cells within a blood sample
JP5966227B2 (ja) * 2011-02-10 2016-08-10 国立大学法人 長崎大学 急性肺損傷診断方法
JP5214042B2 (ja) 2012-02-03 2013-06-19 アンリツ株式会社 光素子パッケージの製造方法
WO2013173493A1 (en) * 2012-05-15 2013-11-21 Manikkam Suthanthiran Non-invasive method of diagnosing renal fibrosis
WO2014029792A1 (en) 2012-08-21 2014-02-27 Qiagen Gmbh Virus particle stabilisation and method for isolating viral nucleic acids
EP2888363B1 (en) * 2012-08-21 2018-06-06 Qiagen GmbH Method for isolating nucleic acids from a formaldehyde releaser stabilized sample
WO2014074501A1 (en) * 2012-11-06 2014-05-15 Quest Diagnostics Investments Incorporated Molecular markers for diagnosis of acute cellular rejection and acute tubular necrosis
WO2014146782A1 (en) 2013-03-18 2014-09-25 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
CA2922746A1 (en) * 2013-09-06 2015-03-12 Immucor Gti Diagnostics, Inc. Compositions and methods for diagnosis and prediction of solid organ graft rejection
WO2015159292A2 (en) * 2014-04-14 2015-10-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. A method and kit for determining the tissue or cell origin of dna
WO2015161880A1 (en) 2014-04-24 2015-10-29 Euroclone S.P.A. An in vitro diagnostic method for cancer by means of circulating, cell-free dna
CA3084920C (en) 2014-07-09 2023-02-28 Exosome Diagnostics, Inc. Methods for isolating microvesicles and extracting nucleic acids from biological samples
WO2018031903A1 (en) 2016-08-12 2018-02-15 Streck, Inc. Molecular reference controls
WO2018035340A1 (en) 2016-08-17 2018-02-22 The Regents Of The University Of California A novel immunoprobe-based method to assess organ injury status through a biofluid-based cell-free dna (cfdna) assay

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120283128A1 (en) * 2009-12-20 2012-11-08 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2014145232A2 (en) * 2013-03-15 2014-09-18 Organ-I, Inc. Methods and compositions for assessing renal status using urine cell free dna

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
V. GARCIA MOREIRA ET AL: "Cell-Free DNA as a Noninvasive Acute Rejection Marker in Renal Transplantation", CLINICAL CHEMISTRY, vol. 55, no. 11, 1 November 2009 (2009-11-01), pages 1958 - 1966, DOI: 10.1373/clinchem.2009.129072 *

Also Published As

Publication number Publication date
JP2019528063A (ja) 2019-10-10
EP3500687A1 (en) 2019-06-26
AU2024202089C1 (en) 2026-03-26
US20240309440A1 (en) 2024-09-19
JP7109424B2 (ja) 2022-07-29
US20200032331A1 (en) 2020-01-30
US11124824B2 (en) 2021-09-21
AU2024202089B2 (en) 2025-12-18
AU2026201931A1 (en) 2026-04-02
US20210024988A1 (en) 2021-01-28
EP3845665A1 (en) 2021-07-07
US11926868B2 (en) 2024-03-12
US20220033892A1 (en) 2022-02-03
CA3033650A1 (en) 2018-02-22
US10982272B2 (en) 2021-04-20
WO2018035340A1 (en) 2018-02-22
US20220333182A1 (en) 2022-10-20
US11505822B2 (en) 2022-11-22
US11753680B2 (en) 2023-09-12
EP3500687A4 (en) 2020-07-29
CN117965692A (zh) 2024-05-03
US10995368B2 (en) 2021-05-04
AU2017313138A1 (en) 2019-03-07
US20210340610A1 (en) 2021-11-04
AU2024202089A1 (en) 2024-05-02
CN109890977A (zh) 2019-06-14
US20190211385A1 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
AU2017313138B2 (en) A novel immunoprobe-based method to assess organ injury status through a biofluid-based cell-free DNA (cfDNA) assay
ES2492498T3 (es) Panel de biomarcadores para el diagnóstico y la predicción de rechazo de injerto
WO2017039359A1 (ko) 트립토파닐 티알엔에이 합성효소를 이용한 감염 질환 또는 감염 합병증의 진단용 조성물과 진단 마커 검출 방법
CN107541563A (zh) 一种用于早期诊断、预测脓毒血症并发急性肾损伤的分子标记物、试剂盒及应用
JP2018517775A (ja) クローン病を治療する方法
JP6192122B2 (ja) 結腸直腸癌診断および予測のためのバイオマーカー
JP2025518766A (ja) 胃癌発病可能性の予測のためのバイオマーカー及びその用途
AU2024202089C8 (en) A novel immunoprobe-based method to assess organ injury status through a biofluid-based cell-free dna (cfdna) assay
CN107541564B (zh) 分子标记物tcons_00016233、试剂盒及应用
ES2902730A1 (es) Metodo para el diagnostico y/o pronostico de esofagitis eosinofilica en saliva
US20200308652A1 (en) Diagnosis and/or prognosis of her2-dependent cancer using moesin as a biomarker
EP2946212A1 (en) Diagnosis of ulcerative colitis
CN113430263B (zh) 基于生物标志物的诊断青光眼的产品及其应用
US20220145397A1 (en) Cancer diagnosis and prognosis
HK40010652A (en) A novel immunoprobe-based method to assess organ injury status through a biofluid-based cell-free dna (cfdna) assay
CN113866415A (zh) 乳腺癌脑转移的诊断及预后标志物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)